Investing.com — イーライリリー・アンド・カンパニー（NYSE:LLY）は日曜日、同社の減量薬ゼプバウンドが、ノボ・ノルディスク（CSE:NOVOb）のウェゴビーと直接比較した臨床試験において、有意に大きな減量効果を示したと発表した。

We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...

業績と展望 2025年第1四半期、Lillyはインクレチン領域（Mounjaro、Zepbound）を中心に強い成長を示しました。特にZepboundは肥満市場で60%以上のシェアを獲得し、肥満治療薬市場の構造変化を牽引しています。経口GLP-1薬「orforglipron」の臨床試験も成功、GLP1/GIP ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...